NHWK
Income statement / Annual
Last year (2022), NightHawk Biosciences, Inc.'s total revenue was $5.98 M,
an increase of 183.08% from the previous year.
In 2022, NightHawk Biosciences, Inc.'s net income was -$43.86 M.
See NightHawk Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$5.98 M
|
$2.11 M
|
$2.95 M
|
$3.05 M
|
$5.79 M
|
$1.52 M
|
$341,643.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$6.40 M |
$691,476.00 |
$12.94 M |
$13.01 M |
$16.23 M |
$8.27 M |
$9.33 M |
$116,000.00 |
$5.25 M |
$1.40 M |
| Gross Profit |
-$420,025.00 |
$1.42 M |
-$9.99 M |
-$9.96 M |
-$10.44 M |
-$6.75 M |
-$8.99 M |
-$116,000.00 |
-$5.25 M |
-$1.40 M |
| Gross Profit Ratio |
-0.07 |
0.67 |
-3.39 |
-3.27 |
-1.8 |
-4.44 |
-26.31 |
0 |
0 |
0 |
| Research and Development
Expenses |
$23.46 M
|
$18.82 M
|
$12.94 M
|
$13.01 M
|
$16.23 M
|
$8.27 M
|
$9.33 M
|
$2.60 M
|
$2.86 M
|
$2.74 M
|
| General & Administrative
Expenses |
$21.13 M
|
$16.83 M
|
$14.93 M
|
$9.43 M
|
$7.03 M
|
$6.37 B
|
$4.14 M
|
$4.36 M
|
$3.98 M
|
$2.43 B
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$6.36 B
|
$0.00
|
$14.07 M
|
$5.35 M
|
-$2.43 B
|
| Selling, General &
Administrative Expenses |
$21.13 M
|
$16.83 M
|
$14.93 M
|
$9.43 M
|
$7.03 M
|
$6.37 M
|
$4.14 M
|
$18.43 M
|
$9.33 M
|
$3.83 M
|
| Other Expenses |
$628,449.00 |
-$965,816.00 |
$188,422.00 |
-$25,557.00 |
$117,780.00 |
$224.29 M |
$670,781.00 |
$14.07 M |
$5.35 M |
$1.40 B |
| Operating Expenses |
$45.22 M |
$35.65 M |
$27.87 M |
$22.44 M |
$23.26 M |
$14.64 M |
$13.47 M |
$21.02 M |
$12.19 M |
$6.56 M |
| Cost And Expenses |
$51.62 M |
$35.65 M |
$27.87 M |
$22.44 M |
$23.26 M |
$14.64 M |
$13.47 M |
$21.02 M |
$12.19 M |
$6.56 M |
| Interest Income |
$987,247.00 |
$815,316.00 |
$566,718.00 |
$431,824.00 |
$265,752.00 |
$22,167.00 |
$31,142.00 |
$66,000.00 |
$40,570.00 |
$10,068.00 |
| Interest Expense |
$2.82 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$549,403.00 |
$364,000.00 |
$73,354.00 |
$79,119.00 |
| Depreciation &
Amortization |
$4.93 M
|
$4.35 M
|
$3.74 M
|
$2.70 M
|
$237,318.00
|
$134,084.00
|
$132,077.00
|
$116,000.00
|
$66,895.00
|
$6,348.00
|
| EBITDA |
-$40.76 M
|
-$31.07 M
|
-$22.38 M
|
-$18.05 M
|
-$16.73 M
|
-$12.96 M
|
-$12.29 M
|
-$20.84 M
|
-$12.08 M
|
-$6.55 M
|
| EBITDA Ratio |
-6.81 |
-14.71 |
-7.59 |
-5.92 |
-2.89 |
-8.53 |
-35.98 |
0 |
0 |
0 |
| Operating Income Ratio
|
-7.64
|
-16.76
|
-8.86
|
-6.8
|
-3.1
|
-8.78
|
-38.42
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1.51 M
|
-$4.38 M
|
-$1.46 M
|
-$944,023.00
|
-$112,404.00
|
-$700,846.00
|
$152,520.00
|
-$100,000.00
|
-$56,000.00
|
-$45,223.00
|
| Income Before Tax |
-$47.15 M |
-$35.55 M |
-$26.38 M |
-$20.34 M |
-$17.58 M |
-$13.22 M |
-$12.97 M |
-$21.12 M |
-$12.24 M |
-$6.61 M |
| Income Before Tax Ratio
|
-7.88
|
-16.82
|
-8.95
|
-6.67
|
-3.03
|
-8.7
|
-37.98
|
0
|
0
|
0
|
| Income Tax Expense |
-$3.29 M |
-$145,974.00 |
$1.31 M |
$45,178.00 |
-$985,488.00 |
-$809,540.00 |
$819,337.00 |
-$463,000.00 |
-$381,040.00 |
$2.18 M |
| Net Income |
-$43.86 M |
-$35.40 M |
-$27.69 M |
-$20.38 M |
-$15.73 M |
-$11.84 M |
-$12.57 M |
-$20.30 M |
-$11.79 M |
-$8.71 M |
| Net Income Ratio |
-7.33 |
-16.76 |
-9.39 |
-6.69 |
-2.72 |
-7.79 |
-36.8 |
0 |
0 |
0 |
| EPS |
-1.72 |
-1.42 |
-1.73 |
-4.29 |
-6.3 |
-21.56 |
-50.05 |
-177.23 |
-127.84 |
-162.73 |
| EPS Diluted |
-1.71 |
-1.42 |
-1.73 |
-4.29 |
-6.3 |
-21.56 |
-50.05 |
-174.92 |
-126.18 |
-160.61 |
| Weighted Average Shares
Out |
$25.55 M
|
$24.87 M
|
$15.98 M
|
$4.75 M
|
$2.50 M
|
$549,334.00
|
$251,231.00
|
$114,509.00
|
$92,212.00
|
$53,534.00
|
| Weighted Average Shares
Out Diluted |
$25.61 M
|
$24.91 M
|
$15.98 M
|
$4.75 M
|
$2.50 M
|
$549,334.00
|
$251,231.00
|
$116,022.00
|
$93,430.00
|
$54,240.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
